Bisphosphonates to Prevent Skeletal Morbidity in Patients with Lung Cancer with Bone Metastases

Price, Nancy; Belani, Chandra P.; Jain, Vinay

doi:10.1016/s1525-7304(11)70347-3

Cited by 19 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A large number of lung cancer patients do not have the option to undergo surgery at the time of initial diagnosis due to the presence of metastases. In total, 30-40% of patients exhibiting advanced lung cancer go on to develop skeletal metastases, which may cause skeletal-related events (SREs), including spinal cord compression, severe bone pain, pathological fractures and potentially life-threatening hypercalcemia of malignancy, requiring treatment with consecutive orthopedic surgery or palliative radiotherapy (2,3). In general, the majority of these patients are treated using systemic therapy or a symptom-based palliative approach.…”

Section: Introductionmentioning

confidence: 99%

Effect of synchronous solitary bone metastasectomy and lung cancer resection on non-small cell lung cancer patients

Zhao

Gao

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

Abstract. Lung cancer is the most frequent cause of cancer-associated mortality among men and women globally. The skeleton is one of the most common metastatic sites. The majority of patients exhibiting bone metastases are treated using systemic therapy or symptom-based palliative approaches without surgery. The present study attempted to improve the therapeutic effects of synchronous surgeries in resectable non-small cell lung cancer patients exhibiting solitary bone metastasis. A total of 5 patients underwent synchronous lung cancer resections and solitary bone metastasectomies between October 2009 and November 2011 in the Department of Cardiothoracic Surgery, Shanghai Sixth People's Hospital (Shanghai, China). All patients had received fluorodeoxyglucose positron emission tomography-computed tomography or bone scintigraphy to demonstrate the presence of solitary bone metastasis and to exclude the presence of metastases at alternative sites. The patients received standard lung cancer and mediastinal lymph node resections. In addition, bone lesions were assessed by orthopedists and operated on synchronously with standard procedures. Following surgery, all patients were administered standard chemotherapeutic regimens. Perioperative indicators, including time for thoracic drainage, length of hospital stay, incidence of post-operative complications and progression-free survival (PFS) time, were observed. The average time for post-operative drainage was 4.6±1.1 days, and the average length of post-operative hospitalization was 8.8±2.2 days. All procedures were performed safely with no serious complications. The PFS of the patients was 13.2±7.7 months. While 2 patients presenting with spinal metastases succumbed at ~1 year post-surgery, the remaining 3 patients presenting with limb bone metastases survived for >16 months post-surgery, and were alive at the last follow-up. In conclusion, the present study indicated that a synchronous metastasectomy and lung tumor resection is a safe method of treatment. The PFS time and survival results demonstrated that on the rare occasion that a patient exhibits solitary bone metastasis, aggressive surgical treatment may be a potential therapeutic option.

show abstract

Section: Introductionmentioning

confidence: 99%

Effect of synchronous solitary bone metastasectomy and lung cancer resection on non-small cell lung cancer patients

Zhao

Gao

et al. 2016

Oncology Letters

View full text Add to dashboard Cite

show abstract

“…Bone metastasis is the most common complication in advanced cancer patients, especially in breast, prostate, and lung cancer. It has been diagnosed at the rate of 30-40 % in advanced nonsmall cell lung cancer (NSCLC) [3]. With the development of new screening methods such as fluorine-18 deoxyglucose positron emission tomography (PET-CT) scan, the detection of bone metastasis in NSCLC increasingly rises [4].…”

Section: Introductionmentioning

confidence: 99%

“…In addition, it is a term used to describe a collection of adverse events associated with bone metastases and include pathological fractures, the requirement for surgery or radiotherapy, spinal cord compression, and malignant hypercalcemia [3,6,7]. A prospective study demonstrated that in over 40 % of NSCLC patients with bone metastasis, SRE developed at least once, and this SRE emerged within the first 5 months [8].…”

Section: Introductionmentioning

confidence: 99%

Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases

et al. 2015

View full text Add to dashboard Cite

Skeletal-related events (SREs) for nonsmall cell lung cancer (NSCLC) patients with bone metastasis lead to serious morbidity. The aim of this study was to determine risk factors for SREs in NSCLC patients with bone metastasis and the factors influencing SRE-free survival and overall survival (OS). From 2000 to 2012, we evaluated retrospectively 835 NSCLC patients. Three hundred and thirty-five of them with bone metastasis were included in the study. SREs and the other prognostic factors were evaluated by univariate and multivariate analysis for SRE-free survival and OS. SREs were detected in 244 patients (72.8 %). The most common SREs were the need for radiotherapy (43.2 %) and malignant hypercalcemia (17.6 %). The median time to first SRE was 3.5 months at the median follow-up of 17 months. A multivariate analysis showed that the presence of bone metastasis at diagnosis (p < 0.001), the number of bone metastasis (p = 0.001), baseline hypercalcemia (p = 0.004), and the presence of palliative radiotherapy (p = 0.04) were independent prognostic factors for SRE-free survival. A logistic regression analysis identified that the presence of bone metastasis at diagnosis [odds ratio (OR), 12.6], number of bone metastasis (OR, 3.05), and baseline hypercalcemia (OR, 0.33) were found to be predictive factors in the developing of SRE. The median OS time for patients with SRE was worse than that for patients without SRE (7 vs 12 months, respectively). For OS, male gender, ECOG performance status (PS), high lactate dehydrogenase (LDH) level, hypoalbuminemia, the presence of bone metastasis at diagnosis, the number of bone metastasis, the presence of SREs, the presence of bisphosphonate therapy, and palliative radiotherapy were independent prognostic indicators for OS by the multivariate analysis. Our results indicated that the frequency of SREs was high and the presence of bone metastasis at the time of diagnosis, baseline hypercalcemia, and multiple bone metastases were significant factors predicting the occurrence of SREs. If bone metastases diagnose earlier, treatments for the prevention of SREs may be initiated earlier; thus, the deterioration of quality of life may be preserved.

show abstract

“…Approximately 30-40% of patients with advanced lung cancer develop skeletal metastases [1,2], which may lead to skeletal complications such as pathological fractures, severe bone pain, spinal cord compression, and potentially life-threatening hypercalcemia of malignancy. In the past, the management of bone metastasis in patients with NSCLC seems to have been neglected due to the short life expectancy of patients (less than 6 months) [3], which does not allow for the manifestation of bone complications.…”

Section: Introductionmentioning

confidence: 99%

“…Traditional therapies such as surgical stabilization or radiotherapy only achieve local control for palliation and unfortunately most patients receiving only local therapy die of progressive systemic disease. Currently, no specific agent reduces the tumor burden of skeletal metastases, although there is some data to support that bisphophates can reduce SREs in patients with NSCLC [1,2,6,7]. It is not easy to select a systemic chemotherapy regimen in patients with NSCLC and bone metastasis because adverse prognostic factors such as poor performance status or old age can influence systemic chemotherapy.…”

Section: Introductionmentioning

confidence: 99%

Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis

Bae¹,

Lee²,

Kim³

et al. 2012

Lung Cancer

View full text Add to dashboard Cite

Bisphosphonates to Prevent Skeletal Morbidity in Patients with Lung Cancer with Bone Metastases

Cited by 19 publications

References 10 publications

Effect of synchronous solitary bone metastasectomy and lung cancer resection on non-small cell lung cancer patients

Effect of synchronous solitary bone metastasectomy and lung cancer resection on non-small cell lung cancer patients

Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases

Prognostic factors for non-small cell lung cancer with bone metastasis at the time of diagnosis

Contact Info

Product

Resources

About